edgen-logo

AI Copilot
portfolioPortfolio

Stocks

Crypto

News
StocksCrypto

Chat History

Aura
Follow our

Join our

EN
Back

Sanofi Secures FDA Approval for Wayrilz, Bolstering Rare Disease Portfolio
Stock NewsThemesSanofi Secures FDA Approval for Wayrilz, Bolstering Rare Disease Portfolio

Sanofi Secures FDA Approval for Wayrilz, Bolstering Rare Disease Portfolio

Edgen StockEdgen Stock·Sep 09 2025, 22:42
Share to
Share to
Copy link
SNYSNY+0.23%SNYNFSNYNF+0.02%
Sanofi Secures FDA Approval for Wayrilz, Bolstering Rare Disease Portfolio
source:
[1] A Look at Sanofi (ENXTPA:SAN) Valuation Following FDA Approval of Breakthrough Rare Disease Therapy (https://finance.yahoo.com/news/look-sanofi-en ...)[2] Sanofi's Wayrilz: A Strategic Breakthrough in the BTK Inhibitor Market for Rare Blood Disorders - AInvest (https://vertexaisearch.cloud.google.com/groun ...)[3] Sanofi's Wayrilz: A Game-Changer in Rare Disease and Immunology Markets - AInvest (https://ainvest.com/sanofis-wayrilz-a-game-ch ...)

Related News

Babcock & Wilcox Secures $40M Refinery Contract
Dec 19 2025, 22:38

Babcock & Wilcox Secures $40M Refinery Contract

Babcock & Wilcox announced on December 19, 2025, that it secured a $40 million contract to supply its Wet Gas Scrubbing technology to a Canadian petroleum refinery, major Canadian petroleum refinery.

Tesla Profits Plunge 53% as Politics Cost 1.26M Sales
Dec 19 2025, 22:29

Tesla Profits Plunge 53% as Politics Cost 1.26M Sales

A Yale study finds Elon Musk's political stance cost Tesla 1.26 million car sales, contributing to a profit drop to $7.1 billion in 2024 from $15 billion in 2023.

Mizuho Lifts Tesla Target to $530 on Robotaxi Hopes
Dec 19 2025, 22:27

Mizuho Lifts Tesla Target to $530 on Robotaxi Hopes

On December 16, Mizuho increased its price target for Tesla to $530, citing growing confidence in the automaker's future robotaxi business.